Pancreatic carcinomas overexpress several matrix metalloproteinases ( MMPs ), in particular MMP2 and MMP9. These enzymes are involved in the degradation of the extracellular matrix to aid tumor cell invasion. The aim of this study was to investigate the effect of TIMP gene therapy on human pancreatic cancer. Human TIMP1 or TIMP2 has been introduced in pancreatic tumor cells under the control of a constitutive promoter using adenoviral vectors, and the effect on tumor invasion observed. It has been demonstrated in vitro that the TIMP -expressing pancreatic tumor cells were significantly less invasive than those cells transfected with a control vector. In vivo, adenoviral delivery of TIMP1 or TIMP2 to nude mice harboring intraperitoneal human pancreatic cancers resulted in prolonged survival compared with control mice if the gene therapy was given early ( P < .009 and P < .0293, respectively ). The in vivo experiments demonstrated evidence of gene transfer by adenoviral vectors to tumor cells and murine mesenteric cells. There was no evidence of transgene expression in distant organs. These experiments have proved the hypothesis that TIMP overexpression in pancreatic cancer cells can modify the invasive phenotype. Also, TIMP gene transfer to human tumor cells is possible both in vitro and in vivo. Cancer Gene Therapy ( 2001 ) A denocarcinoma of the exocrine pancreas is an invasive neoplasm that is usually lethal. Due to the deep, intraabdominal location of the pancreas and a phenotype characterised by early invasion, the cancer tends to present late at an advanced inoperable stage. Despite surgery, radiotherapy, and chemotherapy, the 5 -year survival for a patient with adenocarcinoma of the pancreas is virtually zero.
A denocarcinoma of the exocrine pancreas is an invasive neoplasm that is usually lethal. Due to the deep, intraabdominal location of the pancreas and a phenotype characterised by early invasion, the cancer tends to present late at an advanced inoperable stage. Despite surgery, radiotherapy, and chemotherapy, the 5 -year survival for a patient with adenocarcinoma of the pancreas is virtually zero. 1 Given the typically late presentation of the disease, it is appropriate to concentrate new treatment strategies on limiting pancreatic carcinoma cell invasion.
It is known that the matrix metalloproteinase enzymes ( MMPs ) are involved in proteolysis of the extracellular matrix, aiding tumor cell invasion and the establishment of metastatic deposits. 2, 3 In addition, MMP expression is associated with the neovascularization required for a tumor blood supply to develop. 4 A group of four molecules has been identified, which can specifically inhibit both proenzyme MMPs and active MMPs. 5 -9 These tissue inhibitors of metalloproteinases ( TIMPs ) occur naturally within the extracellular matrix. Pancreatic carcinomas express several MMPs, in particular MMP2 and MMP9, and the level of MMP2 has been directly correlated with the degree of disruption of the basement membrane. 10, 11 Pancreatic tumor samples probed for MMP2 mRNA demonstrate MMP2 in both tumor epithelial cells and stromal cells. TIMP1 and TIMP2 are expressed in the majority of pancreatic tumor epithelia, but not stromal elements. 12 Overall, there is a relative paucity of TIMPs favoring the activities of the MMPs. It is the net balance between the proteases and their inhibitors that is critical to their effect on the environment.
Given that disturbances of the levels of the MMPs and TIMPs are implicated in tumor growth and metastasis, it is logical to attempt to alter the balance by reducing the level of MMP and/ or increasing the level of TIMP. The majority of attention have been focused on the inhibition of the MMP enzyme by synthetic inhibitors or TIMP gene therapy.
Several groups have opted to use the TIMPs themselves as anticancer agents. The first reports of the use of TIMPs as anticancer agents centered on recombinant TIMP1 and TIMP2. Both proteins have been shown to reduce the invasion of malignant cells through membranes in vitro, and limit the development of tumors in vivo. 13 -16 A variety of vectors have been used to transfer TIMP genes in target cells including plasmids, retroviruses, and adenoviruses. Several groups have demonstrated that malignant cells genetically modified to overexpress TIMP1 or TIMP2 form fewer, smaller, and less invasive tumors than control cells in vivo. 17 -21 There have been recent reports of TIMP3 being used for gene therapy and also inhibiting invasion in vitro 22, 23 when delivered by an adenoviral vector. The advantage of TIMP gene therapy is definitive MMP inhibition by the naturally occurring substance that can be produced in excess by cells at the desired location. Genetic manipulation of TIMP levels locally may also avoid the toxicity associated with synthetic MMP inhibitors.
Another area of interest has been that TIMPs may not be inducing an antitumor effect by pure MMP inhibition. TIMP1, TIMP2, and TIMP3 have been demonstrated to reduce angiogenesis in vitro and in vivo, 24 -28 and inhibit the release of latent growth factors in the extracellular matrix. TIMP3 has been shown to be proapoptotic in melanoma, cervical cancer, and vascular smooth muscles. 22, 23 The primary aim of this research was to examine the effect of constitutive expression of TIMP gene products on human pancreatic cancer cells. Replication -defective adenoviral vectors were used to achieve gene transfer. Four pancreatic carcinoma cell lines were genetically modified to overexpress the TIMP proteins and used to assess the effect on invasive behavior in vitro. A second aspect of the project has been the usage of a mouse model that closely resembles advanced pancreatic cancer with peritoneal metastases to examine the effects of adenoviral delivery of TIMP1 or TIMP2 in vivo. Previous work has exclusively focused on the use of recombinant TIMP proteins or TIMP gene transfer for tumors established as subcutaneous xenografts or pulmonary metastases, but this is not representative of the human pattern of pancreatic cancer. Also, generally, the tumor cells were modified ex vivo prior to injection in a murine host. In this study we have attempted to genetically modify the behavior of human pancreatic cancers established in the peritoneal cavities of mice as disseminated metastases.
METHODS

Cell lines and culture conditions
The human pancreatic carcinoma cell lines used in this study were obtained from the following sources: Panc1 obtained from the American Type Culture Collection (Rockwell, MD ); PSN -1 obtained from Dr. T. Sugimura ( National Cancer Center Research Institute, Tokyo, Japan ); and T3M4 obtained from Dr. T. Okabe (University of Tokyo, Tokyo, Japan ). Suit2 / MMP2 is derived from the Suit2 cell line following transfection with the expression plasmid pGW1HG containing the human gene for MMP2 under control of the CMV promoter and was kindly provided by Dr. S. Bramhall (Department of Surgery, University of Birmingham, Birmingham, UK ). Human kidney embryonic cell 293 cells constitutively expressing Adenovirus serotype 5 early 1 proteins were obtained from Microbix ( Toronto, Canada ). T3M4 cells were cultured in RPMI 1640 medium and all other cell lines in Dulbecco's modified Eagle's medium. For all cell lines, the medium was supplemented with 10% heat -inactivated fetal calf serum (FCS ), penicillin ( 100 U / mL ), and streptomycin ( 100 g /mL ).
Generation of recombinant adenoviruses
The human TIMP1 and TIMP2 cDNA were kindly provided in the plasmid vector pGW1HG by British Biotech (Oxford, UK ). The TIMP1 cDNA consisted of a 630 -bp EcoRI / EcoRI fragment corresponding to bases 23 -653 of the published cDNA. The TIMP2 cDNA consisted of a 660-bp HindIII / EcoRI fragment corresponding to bases 255 -915 of the published cDNA (sequencing of the transgene revealed a neutral change from C to T at position 36 compared to the published sequence).
The Adenovirus serotype 2 vector system was obtained from Genzyme (Framingham, USA ). The shuttle vector consists of the 5 0 region of the adenovirus serotype 2 genome ( bases 1-356), a CMV promoter followed by a small multiple cloning site for insertion of the desired transgene, the SV-40 polyadenylation signal, and a further region of adenovirus 2 genome ( 4020 -10685 ).
The second component, Adgal, consists of a serotype 2 adenovirus with an E1 deletion extending through the protein IX sequence, with relocation of protein IX to the E4 locus. The E4 region has been modified to include only ORF6. The Escherichia coli -galactosidase gene (LacZ ) has been inserted in the empty E1 region under the control of the E1 promoter. As there is a region of sequence homology between the Adgal and the Ad2 shuttle plasmid in the presence of 293 cells, homologous recombination can occur as the E1 functions are provided in trans.
The TIMP cDNA were amplified by polymerase chain reaction with primers to add SpeI and MluI restriction sites at the 5 0 and 3 0 ends, respectively, to allow simple cloning in the Ad2 shuttle vector.
TIMP1 primers 5 0 ACTAGTACTAGTGAATTCGAGCT-
0 Downstream. The shuttle plasmids containing TIMP1 or TIMP2 were linearized by restriction with BstBI and the Adgal genome was digested with the restriction endonuclease PshA1 to remove the 5 0 end of the viral DNA including the LacZ gene. The resulting DNA from the two digests was then transfected in 293 cells for homologous recombination and packaging as described. 29 After ultracentrifugation on a cesium chloride gradient and desalting, the total number of adenoviral particles present in the eluate was calculated by measuring the optical density at 260 nm. 30 The titer of the recombinant adenoviral vectors was established by logarithmic limiting dilution on 293 cells. The lowest dilution at which CPE occurred was taken to be the titer of the virus. Adenoviral stocks were screened for replication -competent adenovirus (RCA ) by titration on nonpermissive Panc1 cells.
Adenoviral infection of pancreatic carcinoma cell lines
1Â10
5 human pancreatic carcinoma cells were infected with Adgal virus to give multiplicities of infection ( MOI ) of 10, 50, 100, 500, and 1000 in the presence of 2% FCS. The infected cells were incubated for 18 hours. The medium was removed and replaced with fresh medium plus 10% FCS. Forty -eight hours after infection, the cells were washed with phosphate -buffered saline (PBS ), fixed, and stained for -galactosidase expression [incubated in 1 mg / mL X -gal (5 -bromo -4 -chloro-3-indoyl --D -galactopyranosidase), 10 mM sodium phosphate buffer (pH 7.3 ), 150 mM NaCl, 1 mM MgCl 2 , 3.3 mM K 3 Fe(CN ) 6 , 3.3 mM K 4 Fe( CN ) 6 ].
Assay of TIMP1 and TIMP2 production
5 human pancreatic carcinoma cells were infected with Adgal, AdTIMP1, or AdTIMP2 at an MOI of 100 for Panc1, T3M4, and Suit2 and an MOI of 500 for PSN -1. The cells were then incubated with the adenovirus for 18 hours. Culture medium was then changed and the conditioned medium collected at 24 hours. Cells were detached with trypsin, resuspended, and counted. Supernatants were centrifuged to remove any cellular debris and transferred to sterile microfuge tubes. To assess the time course of TIMP1 or TIMP2 expression by Panc1 cells after infection with the adenoviral vectors, 1Â10
5 cells were seeded in each well of six -well plates. The cells were incubated overnight at 378C in E4 + 10% FCS. Cells were infected at an MOI of 100 with AdTIMP1 or AdTIMP2. The following day, cells were detached with trypsin and seeded on six -well plates at a density of 1Â10 5 cells/well. Supernatants were harvested every 12 hours for a total of 96 hours.
TIMP1 and TIMP2 protein concentrations were determined using the Biotrak 2 TIMP1 ELISA System or the Biotrak 2 TIMP2 ELISA System according to the manufacturer's instructions.
Assessment of invasion by cell lines
3Â10
6 human pancreatic carcinoma cells were infected with Adgal, AdTIMP1, or AdTIMP2 at the appropriate MOI for the cell line. Twenty -four hours after infection, the cells were detached with trypsin, resuspended in medium, and counted. 1Â10 5 cells were seeded in the upper chambers of 12 -well Transwell plates (Costar, Corning, NY ). These consist of an upper chamber whose base is a porous membrane ( 8 m pore size ) and has been coated with reconstituted basement membrane (Matrigel; Becton Dickinson Labware, Franklin Lakes, NJ, USA ). One milliliter of medium plus 10% FCS was added to the lower chamber. The Transwell plates were then incubated at 378C for 72 hours. Cells that had invaded the membranes were then subjected to an MTT assay. Twenty microliters of 5 mg /mL MTT [3 -( 4,5-dimethylthiazole -2-yl ) -2,5 -diphenyltetrazolium bromide ] was added to 1 mL of medium in the lower chamber and incubated at 378C for 2 -4 hours. The upper chambers were then transferred to another 12 -well plate containing 200 L of DMSO in each well. After incubation for 5 minutes at room temperature, the formazan from the cells on the underside of the membrane ( i.e., the cells that have invaded the membrane ) had dissolved in the DMSO. Each sample was transferred to a 96-well plate allowing absorbance to be measured at 560 nm. Absorbance could be plotted on standard curves for each cell line of optical density against cell number. Each experiment was performed four times with nine replicates tested for each sample.
Assessment of apoptosis
Analysis to determine if apoptosis was occurring in genetically modified cells was performed using the Apoptosis Detection System, Fluorescein ( Promega, Southampton, UK ). The human pancreatic cancer cell lines were transduced with adenoviral vectors as described above. After 48 hours, the cells were detached with trypsin and seeded on sterile polylysine-coated slides. The cells were allowed to grow on the slides for 24 hours. The cells were then fixed in 4% paraformaldehyde (in PBS, pH 7.4) for 25 minutes at 48C. The slides were washed twice in PBS. The cells were permeabilized in 0.2% Triton X -100 in PBS for 5 minutes on ice and washed twice with PBS. Cells were covered with 100 mL of equilibration buffer ( 200 mM potassium cacodylate, pH 6.6, 25 mM Tris -HCl, pH 6.6, RIGG AND LEMOINE: TIMP GENE THERAPY 0.2 mM DTT, 0.25 mg /mL BSA, 2.5 mM cobalt chloride ) and left at room temperature for 5 minutes. The equilibration buffer was then tapped off and replaced with incubation buffer (90 L of equilibration buffer, 10 L of nucleotide mix, 2 L of TdT enzyme). The nucleotide mix consists of 50 M fluorescein -12 -dUTP, 100 M dATP, 10 mM TrisHCl, pH 7.6, and 1 mM EDTA. Plastic coverslips were applied and the cells allowed to incubate at 378C for 60 minutes inside a humidified chamber. The slides were protected from direct light. Positive controls consisted of cells treated with DNase I prior to incubation and negative controls consisted of cells incubated in buffer lacking TdT enzyme. The reaction was stopped by immersing the slides in 2Â SSC for 15 minutes. The slides were washed in PBS and then stained with propidium iodide ( 1 g /mL in PBS ) for 15 minutes in the dark. The slides were washed with deionized water three times. One drop of Anti -Fade solution ( Molecular Probes, Cambridge, UK ) was added to the cells and a glass coverslip applied. The edges were sealed. The cells were analyzed using a fluorescent microscope set to 520 nm to view fluorescein and > 620 nm to view propidium iodide.
In vivo experiments
All animals used for the in vivo experiments were female nu /nu mice (ICRF BSU, Clare Hall, South Mimms ). All procedures were carried out according to Home Office regulations and were covered by Home Office License 90 /717.
Human pancreatic carcinoma cell lines were cultured and washed with PBS before being detached from the plates by trypsin, counted, and resuspended. A total of 1Â10 6 cells in 0.1 mL of sterile saline were injected in the peritoneal cavity of each mouse.
Replication -defective adenoviruses Adgal, AdTIMP1, and AdTIMP2 were used for in vivo work. All adenoviruses were prepared as aliquots of 1Â10 9 pfu in 0.5 mL of PBS and 10% glycerol. The adenoviral aliquots were stored at À 708C and thawed on ice prior to administration. Mice received an intraperitoneal injection of 1Â10 6 Panc1 cells on day 0. They then received an intraperitoneal injection of 1Â10 9 pfu adenovirus on day 1, 8, or 15. The primary endpoint was survival.
All mice underwent a postmortem at the time of death. Any ascites present was aspirated and measured. Mouse organs ( spleen, liver, kidney, heart, lungs, and brain ) were weighed, as was any tumor that was present. All organs, tumor, and ascitic fluid were snap -frozen in liquid nitrogen and stored at À 708C.
Assessment of in vivo transgene expression
Mice received 1Â10 6 Panc1 cells as an intraperitoneal injection on day 0. They then received an intraperitoneal injection of 1Â10 9 pfu Adgal on day 1, 8, or 15. The mice were sacrificed 2 or 7 days after the adenoviral administration. Tumor and organs were harvested and were snapfrozen, and composite blocks were mounted in OCT resin. Frozen sections (8 -10 m ) of murine tissue to be stained were thawed and immediately fixed in 0.25% glutaraldehyde and 2% formaldehyde (in PBS ) at 48C for 30 minutes. The sections were then washed in PBS three times for 10 minutes each. Complete X -gal solution was then placed over each section of tissue and the slides incubated overnight in a humidified chamber at 378C. The slides were washed in PBS and postfixed in the same fixation solution. The tissue was counterstained with eosin. The tissue sections were then observed under the light microscope for blue cells. On each occasion that X -gal staining was performed, a positive control of 293 cells infected with an adenovirus expressing -galactosidase was prepared and tested. Another cohort of mice received an intraperitoneal injection of 5Â10 6 Suit2 / MMP2 cells on day 0. They then received an intraperitoneal injection of 1Â10 9 pfu Adgal on day 19 and were sacrificed on day 21. Tumor and organs were harvested and frozen sections prepared. The frozen sections were subjected to staining for -galactosidase expression as described above.
Statistical analysis
ELISA and invasion data were analysed using an unpaired Student's t test and are shown as the mean ± SEM. Statistical significance was defined as P < .05. Analysis of the survival data for the in vivo experiments was performed by the logrank test. These results are expressed as a P value. KaplanMeier curves were also derived. Hazard ratios could be calculated to estimate the risk of death at any time in a particular group. A value of less than 1 suggests a lower risk of death than the control group; likewise, a value greater than 1 suggests a higher risk of death.
RESULTS
Generation of AdTIMP vectors
Replication -incompetent adenoviruses containing cDNA encoding gal, TIMP1, or TIMP2 were successfully generated and purified by three cycles of limiting dilution as described. Restriction endonuclease digestion and Southern blot analysis using 32 P -labelled TIMP1 or TIMP2 probes confirmed the presence of TIMP1 and TIMP2 transgenes.
Large-scale production of the recombinant adenoviruses gave yields of approximately 2Â10 12 total particles per milliliter for each virus. AdTIMP2 was found to have a titer of 3Â10 10 pfu/mL, whereas AdTIMP1 had a titer of 1Â10 11 pfu /mL. Therefore, the ratio of infectious particles to total particles was less than 1:100.
Adenoviral infection efficiency
The optimal MOI for subsequent in vitro work was defined as the number of plaque -forming units per cell required to achieve 100% transduction. Mock -infected Panc1, T3M4, Suit2 /MMP2, and PSN -1 cells were not positive with staining for -galactosidase expression. When infected with Adgal, the optimal MOI was 100 for Panc1, Suit2 /MMP2, and T3M4 cells, and for PSN -1 cells it was 500. These MOIs were used to infect cells in all subsequent in vitro experiments. Toxicity was not observed with MOI < 1000. 
Analysis of transgene expression
To investigate the level of TIMP protein production in the days after adenoviral transduction of tumor cells, supernatants were collected at 12 -hour intervals over 96 hours from Panc1 cells infected with AdTIMP1 or AdTIMP2. TIMP1 expression was low at time 0 and had increased within 12 hours and remained elevated until the final measurement at 96 hours. TIMP2 expression also rose within 12 hours of transduction with AdTIMP2 and was still elevated at 96 hours ( Fig 1 ) .
Effect of TIMP on invasion
Matrigel invasion assays were performed to assess the invasive ability of human pancreatic carcinoma cells infected with Adgal, AdTIMP1, or AdTIMP2. The number of cells invading the lower surface of the membrane was assessed by MTT assay, and from the standard curve for each cell line, the number could be obtained. The results for the four cell lines are shown in Figure 2 . In all cases, there was a significant reduction of invasion by cells infected with AdTIMP1 or AdTIMP2 as compared with Adgal. the mice, the major endpoint was death. The experiment was continued for 26 weeks. Statistical analysis of the survival results for the mice receiving AdTIMP1 at the three time points was performed using the log -rank test ( Fig 3) . There was significantly longer survival for the mice receiving AdTIMP1 on day 1 compared to the control mice (P < .009 ) and the estimated hazard ratio suggested a reduced likelihood of death than the control mice ( .173). Mice treated with AdTIMP1 on day 8 did not have a significant survival advantage over the control mice (P= .145 ), but the estimated hazard ratio suggested a lower risk of death. AdTIMP1 administered on day 15 did not significantly alter survival. When comparing the survival times of the three AdTIMP1 groups, there is strong evidence that the three groups differ significantly ( P <.001 ).
Effect of adenoviral TIMP on cellular apoptosis
The mice that received AdTIMP2 on day 1 of the experiment did have a statistically significant survival advantage compared to untreated control mice (P=.0293 ) ( Fig 4 ) . No survival benefit was seen for the AdTIMP2 treatment on days 8 and 15. The estimated hazard ratio for mice treated with AdTIMP2 on day 1 suggested a lower risk of death than the control mice (.265 ). A log -rank test of the three AdTIMP2 treatment groups showed that there was a significant difference in survival between the groups ( P= .046 ). The administration of Adgal did not show a survival benefit over control for any of the treatment time points at the end of 26 weeks. Tumor burden and volume of ascites. At the time of death, the volume of ascites and tumor weight were measured. Any mice alive and well at 26 weeks were defined as having no tumor. The results were subjected to statistical analysis by a Student's t test. For the mice receiving AdTIMP1 or AdTIMP2 early, there was a significant reduction in tumor weight compared to the untreated control mice (P= .042 and P=.011, respectively ). The intermediate and late administration of AdTIMP1 or AdTIMP2 did not significantly alter tumor weight ( Fig 5 ) . Figure 5 . Graphs demonstrating the mean tumor weight ( a ) and mean volume of ascites ( b ) for the groups of mice that received a single intraperitoneal injection of AdTIMP1. Each treatment group is compared with the control group by a two -sample t test and statistical significance is defined as P < .05 ( denoted as * ). Figure 6 . Graphs demonstrating the mean tumor weight ( a ) and mean volume of ascites ( b ) for the groups of mice that received a single intraperitoneal injection of AdTIMP2. Each treatment group is compared with the control group by a two -sample t test and statistical significance is defined as P < .05 ( denoted as * ).
Cancer Gene Therapy, Vol 8, No 11, 2001 RIGG AND LEMOINE: TIMP GENE THERAPY Similar analyses were performed for the volume of ascites found in each mouse at the time of death. None of the AdTIMP1 -or AdTIMP2-treated groups showed a significant difference in the volume of ascites from the control group ( Fig 6) . Adgal had no effect on tumor weight or volume of ascites at any timepoint. Assessment of gene transfer. It was important to establish the extent of gene delivery by adenoviral vectors in this model of intraperitoneal human pancreatic carcinoma in a nude mouse. Mice were seeded with Suit2 /MMP2 tumors on day 0 received 1Â10 9 pfu Adgal on day 19 and were sacrificed days after the adenoviral injection. Of note, no tumor was seen in the mice bearing Panc1 cells on sacrifice so that only normal organs could be examined. Tissues and tumors were harvested for transgene analysis. The majority of tumors were found around the mesentery and over the pancreas. Therefore, frozen sections were made of these tissues. All six mice showed blue cells around the periphery of the tissues, but also regions of tumor that had infiltrated the pancreas expressinggalactosidase (data not shown ). Sections from composite organ blocks demonstrated that there was no -galactosidase expression in the brain, heart, liver, kidneys, lung, or spleen after the intraperitoneal administration of Adgal to these mice.
DISCUSSION
One of the criticisms of gene therapy is that for many of the approaches to achieve a cure, 100% of the tumor cells would need to be modified. Therefore, strategies that affect nontransduced as well as transduced cells would be of use. The ''bystander effect'' is described for genetic prodrug activation therapy, 31 but the concept also applies to stromal targeting approaches. The stromal and endothelial cells within a tumor play a crucial role in the structure of the extracellular matrix and hence the invasion and angiogenesis that take place. A gene therapy strategy that disrupted the extracellular environment to limit invasion would influence nontransduced and transduced cells alike. This ''field effect'' has been demonstrated by xenograft tumors in nude mice becoming encapsulated in a fibrous layer with restricted invasion after treatment with TIMPs. 17, 20 Other researchers have investigated the behavior of high TIMP -expressing tumor cells. 17, 19, 21 The tumor cells were transfected ex vivo, so while proving the principle of tumor growth limitation by TIMPs, this does not reflect the clinical scenario of using TIMP gene therapy to treat a tumor that is already established. To date, very little work has been published on the in vivo transduction of cells with TIMPs. One group injected retroviral vector producer cells in subcutaneous tumors. The retroviruses that were released encoded TIMP2 cDNA. The growth and invasion of the injected tumors were reduced compared to control tumors. 20 TIMP gene therapy has also been attempted for coronary artery disease. The gene transfer of TIMP2 or TIMP3 to the intimal cells of human saphenous veins limits neointimal thickening in vitro. 32, 33 This work has demonstrated that the modification of human pancreatic carcinoma cells to overexpress TIMP1 or TIMP2 using adenoviral vectors can significantly alter invasion in vitro and prolong survival in a pancreatic cancer animal model. Adenoviral vectors were chosen as they can infect a broad host range, high titers are achievable, and they do not have an envelope to induce complement activation. Replication -incompetent adenoviral vectors encoding the human TIMP1 or TIMP2 cDNA were successfully generated. These adenoviral vectors could be produced in large quantities at satisfactory titer and be shown to be free of replication-competent viruses.
For each cell line, a variety of different MOIs were tested. It was found that for Panc1, T3M4, and Suit2 /MMP2 cells, an MOI of 100 was required to achieve 100% transduction. PSN -1 required an MOI of 500 to achieve 100% transduction. These levels reflect favorably with reports in the literature of between 100 and 1000 adenoviral MOI being necessary to transduce tumor cells. There are several papers that describe the ability of TIMPs to influence apoptosis. 22, 34 This was relevant to the reduction in cellular invasion, as it might have been due to increased apoptosis of modified cells such that there were fewer available to migrate through the matrigel and porous membrane. None of the adenoviruses altered the background level of occasional apoptotic cells.
It was important to try and develop an in vivo model that represented the scenario of a human pancreatic cancer. There have been experiments with orthotropic injection of human tumor cells in the pancreas of an immunosuppressed mouse. While this provides a tumor in the correct anatomical location, it requires laparotomy under general anaesthetic. 35 A less invasive method is the injection of human pancreatic cancer cells into the peritoneal cavity. The tumors form as numerous intraperitoneal nodules and mimic the widespread metastases often seen with intraabdominal cancers. Several groups have demonstrated that this model produces disseminated tumors that can be targeted by gene therapy. 36 -38 Using this model of intraperitoneal pancreatic cancer, we investigated survival in tumor-bearing nude mice following a single injection of an adenoviral vector. AdTIMP1 and AdTIMP2 showed a statistically significant increase in survival for mice that received therapy on the day after tumor seeding. Administration of AdTIMP1 or AdTIMP2 1 or 2 weeks after tumor seeding did not improve survival. The prolonged survival with early administration of AdTIMP1 and AdTIMP2 may reflect the fact that tumor cells were not able to establish themselves in the peritoneal cavity by invasion and promoting angiogenesis. It is possible that administration after tumor cell implantation has occurred is too late to inhibit tumor as it is already established.
In the in vivo experiments, the weight of tumor and the volume of ascites were measured at the time of death. For the mice receiving early AdTIMP1 or AdTIMP2, there was a reduction in tumor burden at 26 weeks compared to the untreated control mice. The intermediate and late administration of AdTIMP1 or AdTIMP2 did not cause a reduction in measurable disease. There was no statistically significant effect on the volume of ascites.
These experiments have shown that TIMP1 or TIMP2 delivered by an adenoviral vector can improve survival in tumor-bearing mice provided that the treatment is given early. This raises difficulties for the clinical setting as the vast majority of pancreatic tumors present late. Therefore, it is possible that for such patients, TIMP administration would be best suited as a combination therapy with cytotoxic agents. Certainly, for a mouse model of lung cancer, it has been shown that a synthetic MMP inhibitor had a synergistic effect when given with cyclophosphamide over either treatment alone. 39 There are other clinical settings in which TIMP gene therapy might be appropriate. As the antitumor effect is most pronounced if the treatment is given early, it might be of use in the perioperative period for patients who have had tumor resections. This could be helpful for patients with intra -abdominal malignancies who are at high risk of tumor recurrence. The occurrence of port site metastases has been described for patients undergoing minimal access surgery who are found to have occult tumors. The use of TIMP gene therapy in this setting might be advantageous. Also, TIMP gene therapy might be considered for palliation of symptoms, e.g., the control of pleural effusions or ascites following fluid drainage.
